Glucose-Responsive Insulin Conjugates With Penta-Valent Sugar Clusters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing controlled-release drug delivery systems fail to provide insulin in proportion to varying blood glucose concentrations, leading to inadequate glycemic control and increased risk of hypoglycemia in diabetic patients.
Innovation Solution
Development of insulin conjugates with penta-valent sugar clusters covalently attached to insulin or insulin analogs, which respond to glucose concentrations by preferentially binding to the insulin receptor at higher glucose levels and the mannose receptor at lower levels, providing a balanced pharmacokinetic and pharmacodynamic profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional controlled-release drug delivery systems are used, then insulin is released slowly over time, but the release is not proportional to varying blood glucose concentrations
Solution Approach 1:
The patent modifies the insulin molecule by conjugating it with sugar clusters (such as mannose or fucose) to create glucose-responsive insulin conjugates. This chemical modification changes the pharmacokinetic parameters of insulin, enabling it to interact with mannose receptors on hepatocytes and other cells in a glucose-dependent manner. At high glucose concentrations, the conjugates are taken up by cells, reducing insulin exposure and preventing hypoglycemia, while at low glucose concentrations, they remain in circulation longer to maintain glycemic control.
Solution Approach 2:
The invention creates a composite structure by combining insulin with sugar clusters (mannose, fucose, or their derivatives) through covalent conjugation. This composite insulin-sugar conjugate exhibits dual functionality: it retains insulin's glucose-lowering activity while gaining glucose-responsive clearance characteristics through the sugar moiety's interaction with mannose receptors, thereby achieving adaptability to varying glucose levels.
2Reliability
If exogenous insulin is administered to replace endogenous insulin, then glycemic control is achieved, but the inability to provide insulin proportional to varying blood glucose concentrations leads to pathological sequelae
Solution Approach 1:
The patent alters the pharmacokinetic parameters of exogenous insulin by conjugating it with sugar clusters, enabling the modified insulin to exhibit glucose-concentration-dependent clearance. This parameter change allows the insulin to be cleared more rapidly at high glucose levels (mimicking physiological insulin dynamics) and maintained longer at low glucose levels, thereby achieving proportionality to varying glucose concentrations and improving reliability of glycemic control.
Solution Approach 2:
The insulin-sugar conjugate system implements a feedback mechanism where blood glucose concentration directly influences insulin clearance and exposure. At high glucose concentrations, the conjugates are preferentially taken up by cells expressing mannose receptors, reducing insulin activity and preventing hypoglycemia. At low glucose concentrations, the conjugates remain in circulation, maintaining glycemic control. This glucose-dependent feedback loop restores physiological insulin dynamics.
3Duration of action of moving object
If simple slow release of insulin is used, then extended duration is achieved, but uncontrolled release increases risk of hypoglycemia
Solution Approach 1:
The patent modifies the clearance rate parameter of insulin by conjugating it with sugar clusters that interact with mannose receptors. This parameter change enables the insulin to be cleared in a glucose-dependent manner: at high glucose levels, rapid clearance prevents hypoglycemia, while at low glucose levels, prolonged circulation maintains glycemic control. This resolves the contradiction between extended duration and hypoglycemia risk.
Solution Approach 2:
The invention transforms insulin from a static slow-release formulation into a dynamic system where clearance and exposure are continuously adjusted based on glucose concentration. The insulin-sugar conjugate exhibits variable pharmacokinetics: it is rapidly cleared when glucose is high (reducing hypoglycemia risk) and maintained when glucose is low (ensuring glycemic control). This dynamic adaptation eliminates the fixed, uncontrolled release profile of conventional formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The insulin conjugates offer improved glycemic control with a lower risk of hypoglycemia by adjusting insulin release based on glucose levels, effectively treating diabetes with enhanced precision.
Implementation Method 1
conjugation of a cluster of sugars, e.g., D-mannose and L-fucose, to insulin has been reported in patent literature that potentially offer such glucose responsive insulins. The cluster of sugar moieties, acting as substrate of endogenous mannose receptor, potentially affect the pharmacokinetic properties of their corresponding insulin conjugates in a way that is sensitive to the endogenous glucose concentration
Data Source
AI summary
An insulin conjugate comprising or consisting of a penta-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide, such as glucose or alpha-methylmannose.